Company / R&D per Share
ImmunityBio, Inc. R&D per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.28
FY2024
5-year range
$0.28 / $0.62
FY2020-FY2024
Trend
-48.6%
vs FY2023
Sector context
#189 of 208
Health Care
What the data says
Among 208 Health Care companies, ImmunityBio, Inc. is in the bottom 9% for r&d per share. R&D per Share has fluctuated over the past 9 years, ranging from $0.02 in FY2016 to $1.42 in FY2020.
Based on SEC 10-K filings.
0.28 in FY2024 with a 5-year CAGR of -27.5%.
Declined from $0.62 to $0.28 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -1.1%
- 5-Year CAGR
- -27.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 208This company $0.28 Sector average $12.19
▼
-97.7% below sector average
Key checks
Key Insights
- In FY2024, r&d per share decreased 48.6% year-over-year.
- Ranks #189 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -7.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $0.28 | -48.6% |
| FY2023 | $0.55 | -11.6% |
| FY2022 | $0.62 | +112.9% |
| FY2021 | $0.29 | -79.3% |
| FY2020 | $1.42 | +0.1% |
| FY2019 | $1.42 | +283.8% |
| FY2018 | $0.37 | +164.5% |
| FY2017 | $0.14 | +611.0% |
| FY2016 | $0.02 | -99.9% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026